New Kinase Inhibitor Approved for Certain Metastatic Breast Cancers
Gedatolisib received its first FDA approval for advanced HR-positive, HER2-negative breast cancer without mutations in PIK3CA. The U.S. Food...
Progress Against Cancer
Gedatolisib received its first FDA approval for advanced HR-positive, HER2-negative breast cancer without mutations in PIK3CA. The U.S. Food...
The RET inhibitor received traditional approval to treat RET-fusion-positive solid tumors. The U.S. Food and Drug Administration (FDA) has...
FDA approves pembrolizumab and enfortumab vedotin-ejfv for patients with muscle-invasive bladder cancer regardless of cisplatin eligibility. The U.S. Food...
The FDA approved isatuximab-irfc as part of three different combination regimens for multiple myeloma. The U.S. Food and Drug...
The allogeneic regulatory T cell therapy was designed to improve HSCT outcomes in patients with hematological malignancies. The U.S....
Sacituzumab govitecan-hziy was approved as a monotherapy or in combination with pembrolizumab. The U.S. Food and Drug Administration (FDA)...
Palbociclib is the first CDK4/6 inhibitor approved for HR-positive, HER2-positive advanced breast cancer. The U.S. Food and Drug Administration...
Afamitresgene autoleucel was granted full approval with an expanded indication for certain adult and pediatric patients with advanced synovial...
The FDA approved capivasertib with abiraterone and prednisone for adults whose metastatic prostate cancer may be sensitive to hormone...
Under new approval, the drug can be given with immunotherapy to help reduce risk of recurrence after surgery in...